Jean-Paul Clozel

Career

1. 2026-03 – 2026-10
   Idorsiasrc
   Chairman and ad-interim CEO
   Took over day-to-day operations when Srishti Gupta stepped down; CEO role passes to Roland Wandeler on 2026-10-01 (PR-2026-07-01)
2. 2024-06 – 2026-03
   Idorsiasrc
   Chairman of the Board (non-executive)
   Elected Chairman at the 2024-06-13 AGM on retiring as CEO; re-elected 2026-05-06 (AGM-2026)
3. 2017-06 – 2024-06
   Idorsiasrc
   Co-founder and CEO
   CEO since the company was created by demerging Actelion's drug discovery and early clinical pipeline when Johnson & Johnson acquired Actelion (USD 30bn, June 2017)
4. 2000 – 2017
   Actelionsrc
   CEO
   Took the CEO role in April 2000 when Actelion listed; the release credits Actelion with launching three blockbuster drugs. A search summary also calls him Chairman and CEO (WS-cdf)
5. 1997 – 2000
   Actelionsrc
   Co-founder
   Co-founded at the end of 1997 with Martine Clozel, Walter Fischli and Thomas Widmann (the co-founder names from WS-cdf)
6. 1985 – 1997
   F. Hoffmann-La Rochesrc
   Cardiovascular drug discovery researcher
   12 years; selected the first calcium T-channel blocker and worked on the first orally active renin inhibitor and anti-thrombotic agents. Start year 1985 from WS-cdf
7. 1980 – 1985
   Clinical practicesrc
   Cardiologist
   The 2024 release says eleven years as a clinician before moving to research

Achievements

• Co-founded Actelion in 1997 and ran it as CEO from its April 2000 listing until Johnson & Johnson bought it for USD 30bn in 2017src
• Co-founded Idorsia from the Actelion demerger in June 2017 and was its CEO for seven years; two drugs launched in that time (insomnia; cerebral vasospasm after subarachnoid hemorrhage)src
• Recipient of the 1997 Hoffmann-La Roche Research Prize; nominated to the Collège de France (Chair of Technical Innovation) in 2007src
• As interim CEO, H1 2026: QUVIVIQ net sales CHF 91m (+62%), a Pharmakon secured term loan of up to CHF 250m repaid the New Money Facility, full-year 2026 guidance reaffirmedsrc

Education

• Medical school in France (institution not named in the sources read), MD Medicine (cardiology)src
• University of Montreal; University of California, San Francisco, Post-doctoral training Pharmacology and physiologysrc

Background

• Family Married to Martine Clozel, Idorsia's EVP & Chief Scientific Officer and an Executive Committee member; the two co-founded Actelion and Idorsia togethersrc
• Founder Jean-Paul and Martine Clozel are Idorsia's largest shareholders, reported at more than 20% at 2025-12-31src
• Investing Was a holder of Idorsia's convertible bonds and among the bondholders who signed lock-up agreements backing the 2025 restructuring of CHF 800m of convertible debtsrc
• Investing In April 2024 the Clozels committed to vote for letting Idorsia repay a maturing convertible in shares and agreed a 180-day lock-up; they took another 180-day lock-up on the October 2025 share offeringsrc
• Other Collège de France annual chair in technological innovation (Liliane Bettencourt chair); publishes widely in peer-reviewed cardiovascular researchsrc